ZBIO
NASDAQ HealthcareZenas BioPharma, Inc. - Common Stock
Biotechnology
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
�� 市场数据
| 价格 | $21.82 |
|---|---|
| 成交量 | 313,578 |
| 市值 | 1.36B |
| RSI（14日） | 69.8 |
| 200日均线 | $23.81 |
| 50日均线 | $23.33 |
| 52周最高 | $44.60 |
| 52周最低 | $8.51 |
| Forward P/E | -4.52 |
| Price / Book | 4.91 |
🎯 投资策略评分
ZBIO 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (71/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🚀 Moon Shot (7/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ZBIO in your text
粘贴任何文章、记录或帖子 — 工具将提取 ZBIO 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.